Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 5Recruiting 4Completed 4Terminated 2Not yet recruiting 2Withdrawn 1Unknown 1Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1Hematologic Neoplasms 1

Interventions

Rituximab 21Cyclophosphamide 15Etoposide 11Vincristine 9Prednisone 9Doxorubicin 8Cytarabine 8Filgrastim 7Radiotherapy 6Peripheral Blood Stem Cell Transplantation 6fludarabine phosphate 5Melphalan 5Dexamethasone 4Carmustine 4Bendamustine Hydrochloride 4loncastuximab tesirine 3ibrutinib 3Tacrolimus 3Stem Cell Transplantation 3Mycophenolic Acid 3Methotrexate 3Gemcitabine 3Calcium Dobesilate 3CT-P10 3Busulfan 3venetoclax 2sargramostim 2polatuzumab vedotin 2pembrolizumab 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, Large B-Cell, Diffuse × tafasitamab × Clear all
NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Karyopharm Therapeutics Inc

Phase 1/2 Withdrawn
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡